KNSA - CIK 0001730430
Kiniksa Pharmaceuticals, Ltd. trades as KNSA and has a market capitalization of $3.75 B, making it the #1624 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $677.56M, up 60.1% from the prior year and net income of $59.01M. This page tracks Kiniksa Pharmaceuticals, Ltd. through 733 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 4 fiscal years Kiniksa Pharmaceuticals, Ltd.'s revenue grew from $38.54M to $677.56M, a compound annual growth rate of 104.8%. Net profit margin expanded from -409.7% to 8.7% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-05-26 |
| SCHEDULE 13D/A | - | 2026-05-26 |
| SCHEDULE 13G/A | - | 2026-05-06 |
| Insider trade | 4 | 2026-05-05 |
| Insider sale notice | 144 | 2026-05-01 |
| Major company event | 8-K | 2026-05-01 |
| Insider trade | 4 | 2026-05-01 |
| Insider trade | 4 | 2026-04-30 |
– ARCALYST ® (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth –
A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com . Individuals interested in participating in the call via telephone may register here . Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.
– Educational campaign to raise awareness of recurrent pericarditis and to empower patients to discuss ARCALYST with their healthcare provider –
Kiniksa Pharmaceuticals to Present at TD Cowen 46th Annual Health Care Conference
The largest companies sharing Kiniksa Pharmaceuticals, Ltd.'s SEC industry classification (pharmaceutical preparations).
Kiniksa Pharmaceuticals, Ltd. (KNSA) has a market capitalization of $3.75 B as of 2026-05-29, ranking #1624 among US-listed companies.
Kiniksa Pharmaceuticals, Ltd. reported revenue of $677.56M for fiscal year 2025, an increase of 60.1% year over year.
Yes. Kiniksa Pharmaceuticals, Ltd. reported net income of $59.01M in its latest fiscal year.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
– ARCALYST ® (rilonacept) Q4 2025 and full year 2025 net product revenue of $202.1 million and $677.6 million, respectively –